Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Indian Journal of Medical and Paediatric Oncology
Search Article 
  
Advanced search 
 
Year : 1998  |  Volume : 19  |  Issue : 4  |  Page : 121-128

Role of paclitaxel as a single agent and in combination with iforfamide in advanced head and neck cancer


Department of Medical Oncology and Surgical Oncology, Tata memorial Hospital, Parel, Mumbai

Correspondence Address:
VR Pai
Department of Medical Oncology and Surgical Oncology, Tata memorial Hospital, Parel, Mumbai

Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

PURPOSE: To evaluate the efficacy of paclitaxel as a single agent and in combination with ifosfamide in advanced or recurrent head and neck cancer patients. PATIENTS AND METHODS: Thirty one male patients with squamous cell carcinoma were entered in this study. Seven patients received paclitaxel (200 mg/m2), as a single agent and twenty four patients received a fixed dose of ifosfamide (1.5 gm/m2) and one of three escalating dose levels of paclitaxel. In group 1-100 mg/m2, in group 11-140 mg/m2, in group 111-175 mg/m2 paclitaxel was given. Premedication was given prior to paclitaxel (dexamethasone, phenargan, ranitidine). The cycles were repeated at an interval of 4 weeks for a total of three cycles. RESULTS: Six evaluable patients received paclitaxel (200 gm/m2) as a single agent. Ifosfamide and escalating doses of paclitaxel. In group 1(100 mg/m2) five patients, in group II (140 mg/m2) seven patients and group III (175 mg/m2) twelve patients were treated. Whereas no response was observed in group I and only one partial response in group II, four complete and four partial responses were observed in group III. There was no dose limiting hematological and neurotoxicity observed. One patient died two days after the first cycle due to cardiac failure and respiratory distress. CONCLUSION: Paclitaxel shows consistent antitumour effect advanced and recurrent head and neck cancer patients as a single agent and in combination with Ifosfamide.


[PDF Not available]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed589    
    Printed44    
    Emailed0    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal